Stock analysts at StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX – Get Free Report) in a research note issued on Tuesday. The brokerage set a “hold” rating on the stock.
Brooklyn ImmunoTherapeutics Stock Performance
Shares of BTX stock opened at $0.25 on Tuesday. Brooklyn ImmunoTherapeutics has a fifty-two week low of $0.17 and a fifty-two week high of $10.10. The firm has a market capitalization of $14.71 million, a price-to-earnings ratio of -0.11 and a beta of 4.61. The stock’s 50-day simple moving average is $0.71 and its 200-day simple moving average is $1.33.
About Brooklyn ImmunoTherapeutics
Featured Articles
- Five stocks we like better than Brooklyn ImmunoTherapeutics
- Investing in Construction Stocks
- Dow Jones: A Relevant Benchmark or a Relic of the Past?
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- 3 Big-Name Stocks Just Announced Big-Time Dividend Increases
- Do ETFs Pay Dividends? What You Need to Know
- Market Overreaction: 2 Stocks to Buy on the Way Down
Receive News & Ratings for Brooklyn ImmunoTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brooklyn ImmunoTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.